Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess the Safety, Tolerability and Effectiveness of Nuedexta (Dextromethorphan 20 mg/Quinidine 10 mg) in the Treatment of Pseudobulbar Affect (PBA)

NCT01799941 is registered in ClinicalTrials.gov with Avanir Pharmaceuticals as lead sponsor.

NCT NCT01799941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01799941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess the Safety, Tolerability and Effectiveness of Nuedexta (Dextromethorphan 20 mg/Quinidine 10 mg) in the Treatment of Pseudobulbar Affect (PBA)
Lead sponsor
Avanir Pharmaceuticals
Phase
Phase 4
Overall status
Completed
Start date
February 28, 2013
Completion date
May 31, 2015
Enrollment
367 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dementia, pseudobulbar affect (pba), stroke, traumatic brain injury (tbi)